logo

Last Update

This profile was last updated on 8/18/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Anthony Rosenberg?

Anthony Rosenberg

Global Head, Mergers and Acquisitions and Licensing ( Corporate

Novartis AG

HQ Phone:  +41 61 324 11 11

Direct Phone: +41 ** *** ** **direct phone

Email: t***@***.com

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Novartis AG

Lichtstrasse 35

Basel, Basel-City,4056

Switzerland

Company Description

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and bi...more

Background Information

Employment History

Managing Director

MPM Capital L.P.


Director

IOMX


Affiliations

arGEN-X N.V

Board Member


Idenix Pharmaceuticals , Inc.

Board Member


Radius Health Inc

Board Member


TRINETX INC

Board Member


Clinical Ink Inc

Board Member


The BioExec Institute

Board Member


Saudi Telecom Company

Board Member


Serodus ASA

Advisor


Pharma

Member of the Executive Committee


Technology Vision Group LLC

Advisory Board Member


Executive Committee Novartis Pharma AG

Head Partnering and Emerging Businesses, Member


PEC

Member


Education

BSc/MSc


Bachelor of Science degree

Biological Sciences

University of Leicester


Masters of Science

Physiology

University College London


Masters of Science

Physiology

University of London.


Web References(109 Total References)


iOmx Therapeutics

iomx.com [cached]

Tony Rosenberg
Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.


Advisor / About Serodus - Serodus ASA

www.serodus.com [cached]

Anthony Rosenberg
Business development and licensing Anthony (Tony) Rosenberg served as Global Head M & A / licensing until February 2015 and in that role was responsible for Corporate M & A / Licensing across all Novartis divisions. This included execution of the Novartis Portfolio Transformation, comprising asset swaps/ divestments across several business sectors, which is currently seen as a unique set of transactions in the industry. Prior to this role Mr. Rosenberg was Global Head Business Development and Licensing, Novartis Pharma for 7 years. Earlier in his career in Novartis he was Head of Transplant /Immunology Global Business Unit , after several marketing leadership roles. Mr. Rosenberg has a B.Sc. (Hons) from University of Leicester, a M.Sc. Physiology from University of London.


Committee Composition - Radius Health, Inc.

ir.radiuspharm.com [cached]

Tony Rosenberg
Anthony Rosenberg has served on our Board of Directors since March 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from December 2012 to March 2013. Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector. Tony Rosenberg Tony Rosenberg Anthony Rosenberg has served on our Board of Directors since March 2015. From January 2013 to February 2015, Mr. Rosenberg served as Corporate Head of M&A and Licensing at Novartis International, a pharmaceutical company. From March 2005 to December 2012, he served as Global Head of Business Development and Licensing at Novartis Pharmaceuticals. Prior to that, Mr. Rosenberg was Global Head of the Transplant and Immunology Business Unit at Novartis Pharmaceuticals from 2000 to 2005. Mr. Rosenberg initially joined Sandoz, a predecessor to Novartis, in 1980. Mr. Rosenberg served as a director of Idenix Pharmaceuticals, Inc. from June 2009 to March 2012 and from December 2012 to March 2013. Mr. Rosenberg holds a B.Sc from the University of Leicester and an M.Sc in physiology from the University of London. We believe Mr. Rosenberg is qualified to serve as a member of our Board of Directors due to his extensive experience in mergers and acquisitions and licensing in the pharmaceutical sector.


Board of Directors | TriNetX

trinetx.com [cached]

Tony Rosenberg
Tony Rosenberg Board Member Tony Rosenberg joined MPM in 2015. Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis (NVS), based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Clinical Ink, Radius and TriNetX and is a former board member at Idenix, all MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.


Anthony Rosenberg

www.bioexecinstitute.com [cached]

You are here: Home/Board of Directors/ Anthony Rosenberg
Anthony Rosenberg Managing Director, MPM Capital Anthony Rosenberg Prior to joining MPM, Tony served as Global Head, M&A and Licensing (Corporate) for Novartis, based in Basel, Switzerland. In this role Tony oversaw the Novartis portfolio transformation, a comprehensive set of transactions announced in 2014 to focus Novartis on its global businesses in innovative pharmaceuticals, eye care and generics. Tony is a Board member at Radius and a former board member at Idenix, both MPM portfolio companies. Tony joined Novartis predecessor company Sandoz in the U.K. in 1980, where he held diverse leadership positions across sales and marketing, business development and strategic planning. He moved to Basel in 1994, assuming roles of increasing responsibility, and in 2000 was appointed Global Head of the Transplantation and Immunology Business Unit. In 2005, Tony was appointed Global Head of Business Development and Licensing (Pharma), and managed over 30 major in-licensing transactions across therapeutic areas as well as numerous divestments. In 2010, he assumed added responsibility leading the Molecular Diagnostics Group. Tony has a Bachelor of Science degree in Biological Sciences from the University of Leicester and a Masters of Science in Physiology from the University of London.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory